Feasibility of Continuous Geriatric Assessments as a Prognostic Indicator in Elderly People with Gastrointestinal Cancer

Hiroshi Kitamura¹, Fumio Nagashima¹, Masahiko Andou² and Junji Furuse¹

Abstract:
Objective The feasibility of continuous geriatric assessments (GAs) has not been evaluated fully in elderly patients with cancer. We prospectively investigated this issue by administering a recommended-GA set (r-GA) repeatedly to patients undergoing chemotherapy for gastrointestinal cancer on an outpatient basis.

Methods We administered the r-GA before chemotherapy and every two months thereafter. Continuous GAs was defined as the completion of at least two assessments, including the pre-treatment evaluation. The r-GA included the Barthel Index (Basic Activities of Daily Living [BADL]), Mini-Mental State Examination-Japanese (MMSE-J), Instrumental Activities of Daily Living (IADL) scale, Vitality Index (VI), and Geriatric Depression Scale-15. We also used the Vulnerable Elders Survey (VES)-13 to screen overall vulnerability. We analyzed the correlations between each baseline GA score and the overall survival (OS) and the association between the OS and changes in each patient’s GA scores over time.

Patients Patients ≥65 years of age who presented to our department for initial consultation were enrolled and followed between December 2012 and January 2017.

Results Twenty-one elderly patients (median age, 76 years old) were enrolled. GAs were completed within 20 minutes. In an age- and performance status (PS)-adjusted Cox proportional hazards analysis, the baseline BADL, MMSE-J, and VI scores correlated significantly with the OS (p=0.012, p=0.032, and p=0.012, respectively). During the clinical course, decreases in the MMSE-J and VES-13 scores were correlated with the OS (p=0.022 and p=0.019, respectively).

Conclusion Outpatient GA administration is feasible. Low baseline BADL, MMSE-J, and VI scores and decreased MMSE-J and VES-13 scores over time may prognosticate the OS.

Key words: ADL, cognitive function, elderly patients with cancer, geriatric assessment

(Intern Med Advance Publication)
(DOI: 10.2169/internalmedicine.2856-19)
erly patients (8, 9).

Recently, the National Comprehensive Cancer Network (NCCN) (10) and the International Society of Geriatric Oncology (SIOG) established guidelines for elderly patients (≥ 65 years of age) with cancer, which include recommendations concerning the use of geriatric assessments (GAs) (11-13). Previously, GAs were performed only once, typically before an intervention. In 2014, the SIOG-GA task force released a consensus agreement regarding the use of GAs in geriatric oncology, including the use of these measures to obtain comprehensive information beyond routine examinations and to predict severe complications, survival outcomes, and treatment approaches. These guidelines facilitated treatment decision-making and the selection and subsequent implementation of appropriate combinations of GAs (14). The American Society of Clinical Oncology (ASCO) determined that the use of GAs was indispensible when treating elderly patients with cancer (15). However, GAs may comprise various measures, and no true consensus currently exists regarding the most appropriate combination of scales.

The component tools of a GA set should be screened to assess their feasibility and effectiveness and determine the appropriateness of the set. The Vulnerable Elders Survey (VES)-13 can be self-administered and completed quickly and is therefore useful for screening vulnerabilities in elderly patients (16). A feasible GA should be concise, quickly completable, and well-correlated with other GA scales. Furthermore, the ideal GA scale should be comprehensive and provide additional relevant information (17). Outpatients often exhibit progressive reductions in activities of daily living (ADL) performance and their cognitive function, and GAs can be applied to these patients before and after chemotherapy to help assess therapeutic efficacy. However, the significance of continuous GAs has yet to be demonstrated (17, 18). The present study investigated the feasibility of administering continuous GAs in elderly patients undergoing chemotherapy for gastrointestinal cancer.

**Methods**

**Study design**

This prospective observational pilot study was conducted to evaluate the feasibility of regular GA application in elderly patients diagnosed with unresectable and postoperative recurrences of solid gastrointestinal cancers who were scheduled for chemotherapy. We recruited approximately 10 patients who were considered “young-old” and another 10 patients considered “old-old.” Patients >75 years old, described as “super elderly,” were also included in the study population.

Patients were screened using selected GAs before chemotherapy and every two months thereafter. We sought to evaluate 1) whether or not continuous GA application was feasible; 2) the correlation between each baseline GA score and the overall survival (OS), which would inform decision-making with regard to treatment intensity or as a prognostic marker; and 3) the correlation between the OS and changes in the GA scores over time during treatment.

**GAs**

GAs were administered as recommended by the Japanese Study Group, in accordance with the Guidelines of the Comprehensive GAs (CGAs). The “Japanese Study Group based on the Guidelines of the CGA” includes members of the CGA Guidelines for Decisions in Longevity Science Research Project of Health Science Research Grants in the 2,000 General Project Research Field. The GAs included the Barthel Index, Mini-Mental State Examination (MMSE), Lawton and Brody Instrumental ADL (IADL) score, Vitality Index (VI), Geriatric Depression Scale (GDS)-15, and VES-13 (19, 20), and their combination was designated the recommended GAs (r-GAs). For each patient, the r-GAs were initially performed before the first chemotherapy session and then repeated every two months after chemotherapy initiation. We spaced these assessments at two-month intervals to match the standard-of-care intervals between computed tomography assessments used to determine the effectiveness of chemotherapy. The r-GAs were administered a maximum of 7 times over 12 months. We discontinued their administration when a direct assessment was no longer possible (e.g. primary disease exacerbation). Assessments were considered “continuous” if a minimum of two data points were collected, including before the start of treatment and after two months. The r-GAs were conducted by a professional assistant, and assistance was provided by the assistant or family members as long as the scores of each GA were not affected. The following items were assessed continuously:

1) **Geriatric Assessment:**

   (1) Basic ADL (BADL) was evaluated using the Barthel Index (21), which comprises 10 questions pertaining to ADL, such as feeding, mobility, and grooming. All scores were weighted, and the maximum score was 100 points (100 points = PS0).

   (2) Cognitive function: We used the Japanese author-certified version of the MMSE (MMSE-J) (22), which we purchased from the publisher (Nihon Bunka Kagakusha, Tokyo, Japan). The maximum test score is 30, and the lower cut-off limit is 23/24. A lower score indicates a decline in functional cognition.

   (3) Emotions/moods were assessed using the GDS-15, which assesses depression in elderly patients (23). The questions were identical to those included in the GDS-Short Form (SF) (24). This yes/no questionnaire comprises 15 questions about feelings and moods. A score ≥5 indicates a tendency toward depression, while a score ≥10 indicates the presence of depressive symptoms.

   (4) IADL: The Japanese version of the IADL scale (Lawton and Brody) has been validated (25) and shown to correlate positively with the MMSE and GDS (26). This scale evaluates various ADL, including 1) using the telephone, 2)
considered statistically significant.

A continuous r-GA scores and the OS using a Cox regression. To determine the predictive value of r-GA scores for the OS, we first assessed the normality of continuous variables. To determine the differences in maximum scores.

The third quartile is 14.30%. Sex Male 14 66.70%
Female 7 33.30%

The first quartile is 71 - The third quartile is 83 - 

ECOG (PS) 0 11 52.40%
1 8 38.10%
2 2 9.50%

Clinical Stage (UICC) III 3 14.30%
IV 18 85.70%

Patients

The study protocol was approved by our institutional review board, and all patients provided their written informed consent before study enrollment in accordance with the principles of the Declaration of Helsinki. Elderly patients who presented to the Faculty of Medical Oncology at Kyorin University Hospital for an initial consultation were enrolled and followed from December 2012 to January 2017. The maximum total follow-up duration was two years.

The following study inclusion criteria were applied: 1) ≥ 65 years old, 2) a diagnosis of unresectable or recurrent solid gastrointestinal cancer, and 3) scheduled to receive first-line outpatient chemotherapy. We excluded patients with non-cancerous conditions that might reduce their cognitive function and/or the ability to perform ADL. We also measured the following serum parameters that might influence the ADL or cognitive function: iron, trace elements (copper, zinc), nutrients (vitamins B1, B2, and B12, folic acid), and thyroid-related hormones (thyroid-stimulating hormone [TSH], free triiodothyronine [FT3], and free thyroxine [FT4]). If reductions in the ADL performance or cognitive function were noted, we performed standard blood counts and blood biochemistry tests after enrollment. If we suspected a deficiency in any of these factors, we suspended treatment until appropriate supplementation had been administered.

Table 1. Patients’ Backgrounds.

| Age (years) | Patients (n=21) % |
|-------------|------------------|
| Median 75 - |
| Range 67–86 - |
| The first quartile 71 - |
| The third quartile 83 - |

Sex Male 14 66.70%
Female 7 33.30%

ECOG (PS) 0 11 52.40%
1 8 38.10%
2 2 9.50%

Primary tumour Colorectal 6 28.50%
Pancreas 4 19.00%
Stomach 3 14.30%
Liver 3 14.30%
Biliary tract 3 14.30%
Oesophagus 1 4.80%
Duodenum 1 4.80%

Clinical Stage (UICC) III 3 14.30%
IV 18 85.70%

Patients’ characteristics

We enrolled 21 patients with unresectable solid gastrointestinal cancers. Tables 1 and 2 show the characteristics of the patients and the administered anticancer drugs. In all patients, the levels of vitamins B1, B2, and B12; folic acid; copper; zinc; and thyroid-related hormones were within the standard ranges (Table 3A). The results of pre-treatment blood tests revealed mild iron-deficiency anemia and low ferritin levels in four patients. We started iron supplementation with these individuals and delayed r-GA performance until the blood iron and ferritin levels had normalized. Three of these four patients died within two months after chemotherapy induction. The remaining patient experienced a resolution of anemia symptoms and received chemotherapy for 12 months. A follow-up revealed that the patient’s serum Fe and ferritin levels had returned to normal (Table 3B).

Continuous assessments (at least 2 data points) were possible in all 21 patients. One r-GA session required approximately 15-20 minutes (maximum: 35 minutes) to complete. All 7 observations were completed in 7/21 patients (33.3%) over a 12-month period. In 12 patients (57.2%), the observations were discontinued mid-study because of cancer progression; however, each of those patients were able to complete between 2 and 6 observations. For the other 2 patients

Results

Statistical analyses

Data were analyzed using the Statistical Analysis Software (SAS) for Windows, version 9.3 (SAS Institute Inc., Cary, NC, USA). The Kolmogorov-Smirnov test was used to assess the normality of continuous variables. To determine the predictive value of r-GA scores for the OS, we first analyzed the correlations between the baseline r-GA scores and the OS and then the correlations between the changes in continuous r-GA scores and the OS using a Cox regression model after adjusting for age and PS. A $P$-value $<0.05$ was considered statistically significant.

Table 1. Patients’ Backgrounds.

| Age (years) | Patients (n=21) % |
|-------------|------------------|
| Median 75 - |
| Range 67–86 - |
| The first quartile 71 - |
| The third quartile 83 - |

Sex Male 14 66.70%
Female 7 33.30%

ECOG (PS) 0 11 52.40%
1 8 38.10%
2 2 9.50%

Primary tumour Colorectal 6 28.50%
Pancreas 4 19.00%
Stomach 3 14.30%
Liver 3 14.30%
Biliary tract 3 14.30%
Oesophagus 1 4.80%
Duodenum 1 4.80%

Clinical Stage (UICC) III 3 14.30%
IV 18 85.70%
### Table 2. Cancer Type and Treatment Regimens for All Patients.

| Type of cancer          | n | Age (years) / Sex | Regimen                        | Session periods (months) |
|-------------------------|---|-------------------|--------------------------------|--------------------------|
| Oesophageal             | 1 | 70/M              | 5-FU+CDDP                      | 2                        |
| Duodenal                | 1 | 81/F              | S-1†                           | 2                        |
| Gastric                 | 3 | 76/M              | S-1†                           | 6                        |
|                         |   | 74/M              | 1st S-1†                       | 12                       |
|                         |   |                   |                                | 2nd weekly PTX           |
|                         |   | 81/M              | S-1†                           | 12                       |
| Hepato-cellular         | 3 | 76/F              | sorafenib                      | 6                        |
|                         |   | 82/M              | sorafenib                      | 12                       |
|                         |   | 86/M              | sorafenib                      | 12                       |
| Biliary tract and/or gall bladder | 3 | 67/F              | GEM+CDDP                       | 2                        |
|                         |   | 68/M              | GEM+CDDP                       | 8                        |
|                         |   | 69/M              | 1st GEM+CDDP                   | 12                       |
|                         |   |                   |                                | 2nd S-1†                 |
| Pancreatic              | 4 | 69/F              | GEM                            | 2                        |
|                         |   | 86/M              | GEM                            | 2                        |
|                         |   | 72/F              | GEM                            | 8                        |
|                         |   | 71/F              | 1st S-1                        | 10                       |
|                         |   |                   |                                | 2nd GEM                 |
| Colorectal              | 6 | 81/M              | 1st mFOLFOX4                   | 2                        |
|                         |   | 85/F              | Capecitabine                   | 2                        |
|                         |   | 73/M              | Capecitabine+OX                | 6                        |
|                         |   | 85/M              | Cetuximab                      | 10                       |
|                         |   | 72/M              | mFOLFOX4                       | 12                       |
|                         |   | 83/F              | Capecitabine                   | 12                       |

† Alternative regimen; 2 weeks chemotherapy and 1-week rest, † Original regimen; 4 weeks chemotherapy and 2 weeks rest. 5-FU: 5-fluorouracil, CDDP: Cisplatin, PTX: Paclitaxel, GEM: Gemcitabine, OX: Oxaliplatin. IRI, Irinotecan; mFOLFOX4, modified Folinic acid, (5-) Fluorouracil, and Oxaliplatin 4

(9.5%), we discontinued observation because one withdrew consent for further observation and the other died of an acute heart attack. We showed the scores of all r-GAs as graphs (Figure), along with the average and standard deviation for each session (Table 4).

**Correlation between r-GA scores and the OS at baseline and through the clinical course of the disease**

When assessing the r-GAs, we noted a significant correlation between the OS and the baseline BADL, MMSE-J, and VI scores (P=0.01, p=0.03, and P=0.01, respectively) after adjusting for the age and PS (Table 5). We did not observe any significant relationship between the OS and a change in PS (P=0.473) after adjusting for age (Table 6A). Nonetheless, the OS was significantly associated with reductions in MMSE-J and VES-13 scores throughout the clinical course (P=0.022 and P=0.019, respectively) after adjusting for the age and PS (Table 6B).

**Discussion**

This study evaluated elderly patients with cancer (≥65 years of age) who underwent repeated r-GAs before chemotherapy and every 2 months thereafter during evaluation sessions with durations of approximately 20 minutes. The r-GA set appears feasible for use in this cohort and in daily clinical practice. When we analyzed the correlation between the baseline r-GA scores and OS, we found that the BADL, MMSE-J, and VI values were useful prognostic indicators. The BADL and VI are patient-reported outcomes (PROs) and can be administered more simply and rapidly than the MMSE-J. PROs can typically be completed by outpatients during waiting periods. However, because these measures are self-administered, they may suffer from a lack of objectivity. If this limitation is pronounced, the MMSE-J or another more objective cognitive function test that correlates with the MMSE-J can and should be considered.

In addition, the OS was found to be positively correlated with lower MMSE-J and higher VES-13 scores, suggesting that changes in these scores serve as prognostic indicators of the survival, even when the scores were initially within normal ranges. One previous study identified a correlation between the survival and pre-treatment MMSE-J scores (18). However, we found no previous studies that performed r-GAs continuously at two-month intervals. We postulate that continuous assessments may help practitioners understand their patients’ conditions during periods of rapid symptom...
Table 3. (A) Levels of Minerals (Zn, Fe, and Cu), Vitamins (vitamins B1, B2, B12, and Folic Acid), and Thyroid-related Hormones (TSH, FT3, and FT4), (B) in Four Patients, Changes in Fe, Hemoglobin (Hgb), and Ferritin Levels with Iron-deficiency Anemia were Noted before and after Fe Supplementation.

| (A) | Items | Unit | Normal range | Range | Average | 95% CI |
|-----|-------|------|--------------|-------|---------|--------|
| Zn  | (μg/dL) | 59–139 | 57–84 | 67.75 | 63.52 | 71.98 |
| Fe  | (μg/dL) | 80–180 | 11–176 | 91.75 | 67.84 | 115.66 |
| Cu  | (μg/dL) | 66–130 | 99–130 | 119.1 | 114.85 | 123.35 |
| Vitamin B1 | (ng/mL) | 21.3–81.9 | 21.3–81.3 | 40.0 | 33.01 | 47.02 |
| Vitamin B2 | (μg/dL) | 4.1–8.8 | 4.1–9.8 | 5.69 | 4.99 | 6.38 |
| Vitamin B12 | (pg/mL) | 233–914 | 238–911 | 540.7 | 449.7 | 631.6 |
| Folic acid | (ng/mL) | 3.6–12.9 | 3.6–20 | 9.04 | 6.87 | 11.21 |
| TSH | (μIU/mL) | 0.41–5.27 | 0.88–5.2 | 2.72 | 2.02 | 3.42 |
| FT3 | (pg/mL) | 1.63–3.20 | 1.61–2.97 | 2.37 | 2.2 | 2.55 |
| FT4 | (ng/dL) | 0.73–1.53 | 0.84–1.54 | 1.16 | 1.07 | 1.26 |

| (B) | Fe (80–180 μg/dL) | Ferritin (male: 25–280/female; 18–60 ng/mL) | Hgb (male: 13.5–17.0/female: 11.5–15.5 g/dL) | GA observation period |
|-----|-----------------|---------------------------------|---------------------------------|---------------------|
| Baseline | After Fe supplementation | Baseline | After Fe supplementation | Baseline | After Fe supplementation | (months) |
| 15 | 60 | 12 | 19 | 11.7 | 11 | 2 |
| 11 | 80 | 9 | 20 | 10.3 | 9.8 | 2 |
| 26 | 72 | 18 | 131 | 10.3 | 13.6 | 2 |
| 24 | 88 | 15 | 100 | 9.9 | 11.8 | 12 |

CI: confidence interval, GA: geriatric assessment

Figure. Graphs of all GA scores for all patients. (A) Barthel Index, (B) MMSE-I, (C) GDS-15, (D) IADL, (E) Vitality Index, and (F) VES-13. GA: geriatric assessment, MMSE-J: Mini-Mental State Examination, Japanese version, GDS: Geriatric Depression Scale, VES: Vulnerable Elders Survey

progression or when the underlying factors cannot be identified based on blood biochemical examination results alone. Given the results of these two analyses, we speculate that patients with low BADL scores and poor cognitive functioning at baseline may demonstrate a poor prognosis, regardless of treatment. Caution should be exercised if a cognitive decline and progressively increasing vulnerability are observed during the clinical course of the disease, even in patients with normal cognition or pre-treatment vulnerabilities.

The ideal frequency of GA is still being debated. However, we have identified numerous benefits associated with the continuous administration of GAs. Reductions in the cognitive function and BADL and VI scores over the course of regular assessments (every one to two months) may indicate changes in the cognitive function and correspond with disease progression. Thus, detailed GAs, when combined
manifests differently in different organs, and each cancer re-

Table 4. the Average Scores of All R-GAs from the Baseline to 12 Months After. Assessments were Considered "continuous" If a Minimum of Two Data Points were Collected, Including before the Start of Treatment and after Two Months.

| GA   | Session periods (months) | Baseline | 2 months | 4 months | 6 months | 8 months | 10 months | 12 months |
|------|--------------------------|----------|----------|----------|----------|----------|-----------|-----------|
|      | N                        | 21       | 21       | 16       | 14       | 11       | 9         | 7         |
| BADL | Average                  | 98       | 96       | 92       | 94       | 100      | 100       | 96        |
|      | S.D.                     | 6.2      | 6.4      | 18.5     | 15.0     | 1.5      | 0.0       | 9.4       |
| MMSE | Average                  | 24       | 25       | 25       | 26       | 27       | 29        | 29        |
|      | S.D.                     | 5.4      | 4.7      | 5.3      | 5.5      | 5.2      | 0.9       | 1.8       |
| GDS15| Average                  | 3        | 4        | 3        | 3        | 4        | 5         | 4         |
|      | S.D.                     | 2.7      | 3.4      | 3.5      | 3.1      | 3.9      | 4.3       | 5.0       |
| IADL | Average                  | 0.9      | 0.9      | 0.8      | 0.8      | 1.0      | 1.0       | 0.9       |
|      | S.D.                     | 0.16     | 0.22     | 0.27     | 0.29     | 0.08     | 0.07      | 0.38      |
| Vitality Index | Average               | 9.8      | 9.5      | 9.8      | 9.2      | 9.7      | 9.9       | 9.6       |
|      | S.D.                     | 0.6      | 1.0      | 0.5      | 1.3      | 0.9      | 0.3       | 1.1       |
| VES-13| Average                | 3        | 3        | 3        | 3        | 2        | 2         | 3         |
|      | S.D.                     | 2.8      | 2.9      | 2.7      | 2.8      | 2.1      | 2.1       | 3.5       |

S.D.: standard deviation, GA: geriatric assessment, BADL: basic activities of daily living, IADL: instrumental ADL, VES: Vulnerable Elders Survey, GDS: Geriatric Depression Scale, MMSE-J: Mini-Mental State Examination-Japanese

Table 5. the correlation between Baseline R-GA Scores and Overall Survival. Age, PS-Adjusted Cox Proportional Hazards Analysis, 95% CI, p<0.05.

| GA scores at baseline | Age, PS-Adjusted Hazard Ratio (95% CI) | p value |
|-----------------------|----------------------------------------|---------|
| Basic ADL             | 1.43 (1.081-1.888)                     | 0.012   |
| MMSE-J                | 0.84 (0.721-0.986)                     | 0.032   |
| Vitality Index        | 0.11 (0.019-0.608)                     | 0.012   |

CI: confidence interval, GA: geriatric assessment, ADL: activities of daily living, IADL: instrumental ADL, VES: Vulnerable Elders Survey, GDS: Geriatric Depression Scale, MMSE-J: Mini-Mental State Examination-Japanese

with blood chemistry and imaging, can enhance comprehensive assessments, guide treatment planning, and inform decisions regarding the continuation of chemotherapy. Further research is needed to determine the ideal interval between assessments. Although a previous study reassessed 202 elderly patients with cancer after 6 months, the authors provided no rationale for this choice of interval (17). A previous study examined GDS-15, IADL, ADL, and MMSE scores before chemotherapy initiation and three and six months after in patients with colon and breast cancers; however, both of these malignancies have relatively long disease courses (18). These findings suggest that reassessments should be timed in consideration of the cancer type and chemotherapy regimen.

This study had some limitations that warrant consideration. First, as this was a pilot study, we enrolled only 21 patients with varying types of gastrointestinal cancers, all of whom were undergoing different treatment regimens. Cancer manifests differently in different organs, and each cancer requires a specific treatment approach. Consequently, various

Table 6. (A) Age-adjusted Cox Proportional-hazards Analysis. (B) Age, PS-adjusted Cox Proportional Hazards Analysis, 95% CI, p<0.05. BADL, MMSE-J, Vitality Index, VES-13, IADL, and PS were Evaluated Every 2 Months from the Time of Enrolment up to 12 Months after Enrolment and Treated as Time-dependent Variables.

(A)

| Scales       | Age-Adjusted Hazard Ratio (95% CI) | p         |
|--------------|-----------------------------------|-----------|
| BADL         | 0.979 (0.955–1.004)               | 0.095     |
| MMSE-J       | 0.899 (0.821–0.983)               | *0.020    |
| GDS 15       | 1.109 (0.988–1.245)               | 0.080     |
| Vitality Index | 0.661 (0.410–1.065)            | 0.089     |
| VES-13       | 1.237 (1.021–1.500)               | *0.030    |
| IADL         | 0.990 (0.976–1.005)               | 0.198     |
| PS           | 0.933 (0.773–1.127)               | 0.473     |

(B)

| Scales       | Age, PS-Adjusted Hazard Ratio (95% CI) | p         |
|--------------|---------------------------------------|-----------|
| BADL         | 0.979 (0.955–1.004)                   | 0.101     |
| MMSE-J       | 0.901 (0.824–0.985)                   | *0.022    |
| GDS 15       | 1.127 (0.991–1.280)                   | 0.068     |
| Vitality Index | 0.643 (0.396–1.044)                  | 0.074     |
| VES-13       | 1.276 (1.041–1.564)                   | *0.019    |
| IADL         | 0.989 (0.973–1.004)                   | 0.143     |

CI: confidence interval, GA: geriatric assessment, ADL: activities of daily living, BADL: basic ADL, IADL: instrumental ADL, VES: Vulnerable Elders Survey, GDS: Geriatric Depression Scale, MMSE-J: Mini-Mental State Examination: Japanese version, PS: performance status
anticancer drugs can produce different adverse events, which can in turn affect GA scores. Additional GA data are required for each cancer type and the associated treatment regimens. Second, a reduced cognitive function may have affected the patients’ responses to screening questions. Therefore, the use of a highly objective scale instead of a questionnaire may provide a better understanding of the patients’ overall condition in cases where reductions in cognition are evident. All patients included in this study were enrolled from a single center. Therefore, prospective studies should consider a multicenter trial approach to encourage appropriately tailored treatment decisions and facilitate the generalization of the findings. Third, the process of subject recruitment took a considerable amount of time. The young-old patients underwent chemotherapy for a median duration of six months. Patients in the young-old population group with a relatively good condition tended to refuse to participate in this study. Accordingly, the participants tended to be rather frail, and many were facing decisions regarding their ability to continue chemotherapy. Furthermore, patients >80 years old [above you said >75 years old was super elderly] (i.e., “super elderly”) underwent a median of 4 months of chemotherapy. We saw approximately 160 patients within this group over a 4-year period, during which we recruited 0-1 patient per month. Elderly patients often do not undergo aggressive treatment like chemotherapy and are likely to receive less burdensome treatment (irradiation if possible) and/or best supportive care (palliative care). Their treatment decisions may be biased by their families and doctors and not entirely reflect the intention of the patients themselves. Finally, future studies should evaluate the effects of social support groups on elderly patients with cancer (29).

In conclusion, we confirmed that the continuous performance of GAs was feasible in elderly (>65 years old) patients with cancer when the r-GA set was administered before treatment and every 2 months thereafter. Second, we found that the BADL, MMSE-J, and VI values were correlated significantly with the OS. These indexes therefore appear to be useful screening tools to supplement PS. Finally, observed reductions in the MMSE-J and VES-13 scores over time were correlated significantly with the OS, suggesting that these scores are useful as prognostic indicators for the survival. GAs reveal a patient’s general condition and provide insights into how a patient interacts with his or her surroundings. As this information cannot be obtained purely by reviewing hospital-based medical records or examination results, we believe that GAs can help clarify the best course of action when treating elderly patients with cancer, including deciding whether or not treatments such as chemotherapy are optimal or will unduly burden the patient.

The authors state that they have no Conflict of Interest (COI).

Acknowledgments

This research received funding from the Department of Medical Oncology, Kyorin University Faculty of Medicine. We want to thank Editage for the English language editing.

Information about grants

This research received funding from the Department of Medical Oncology, Kyorin University Faculty of Medicine.

References

1. Nakatani T, Akechi T, Takayama T, et al. Characteristics of elderly cancer patients’ concerns and their quality of life in Japan: a Web-based survey. Jpn J Clin Oncol 44: 448-55, 2014.
2. Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 27: 2728-2765, 2009.
3. Hurria A, Dale W, Mooney M, et al. Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations. J Clin Oncol 32: 2587-2594, 2014.
4. Lichtman SM, Baldacci L, Aapro M. Geriatric oncology: a field coming of age. J Clin Oncol 25: 1821-1823, 2007.
5. Repetto L, Comandini D. Cancer in the elderly: assessing patients for fitness. Crit Rev Oncol Hematol 35: 155-160, 2000.
6. Baldacci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist 5: 224-237, 2000.
7. Repetto L, Fratino L, Audioso RA, et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol 20: 494-502, 2002.
8. Yates J, Chalmer B, McKeeney FP. Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer 45: 2220-2224, 1980.
9. Hurria A, Mohile S, Gajra A, et al. Validation of a prediction tool for chemotherapy toxicity in older adults with cancer. J Clin Oncol 34: 2366-2371, 2016.
10. NCCN. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines) Senior Adult Oncology; version 2. 2014.
11. Hurria A. Management of elderly patients with cancer. J Natl Compr Canc Netw 11: 698-701, 2013.
12. Extermann M, Aapro M, et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 55: 241-252, 2005.
13. Balducci L, Yates J. General guidelines for the management of older patients with cancer. Oncology (Willis Park) 14: 221-227, 2000.
14. Wildiers H. SIOG consensus on geriatric assessment in older cancer patients. J Geriatr Oncol 5: S1-S2, 2014.
15. Mohile SG, Dale W, Sommerfield MR, et al. Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology. J Clin Oncol 36: 2326-2347, 2018.
16. Luciani A, Ascione G, Bertuzzi C, et al. Detecting disabilities in older patients with cancer: comparison between comprehensive geriatric assessment and vulnerable elderlies survey-13. J Clin Oncol 28: 2046-2050, 2010.
17. Aaldriks AA, Maartense E, le Cessie S, et al. Predictive value of geriatric assessment for patients older than 70 years, treated with chemotherapy. Crit Rev Oncol Hematol 79: 205-212, 2011.
18. Minisini AM, De Faccio S, Ermacona P, et al. Cognitive functions and elderly cancer patients receiving anticancer treatment: a prospective study. Crit Rev Oncol Hematol 67: 71-79, 2008.
19. Toba K. [The guideline for comprehensive geriatric assessment]. Nihon Ronen Igakkai Zasshi 42: 177-180, 2005.
20. Comprehensive Geriatric Assessment guideline. First ed. T Kenji,
21. Mahoney FI, Barthel DW. Functional evaluation: The Barthel Index. Md State Med J 14: 61-65, 1965.
22. Vertesi A, Lever JA, Molloy DW, et al. Standardized Mini-Mental State Examination. Use and interpretation. Can Fam Physician 47: 2018-2023, 2001.
23. Mitchell AJ, Bird V, Rizzo M, Meader N. Diagnostic validity and added value of the Geriatric Depression Scale for depression in primary care: a meta-analysis of GDS30 and GDS15. J Affect Disord 125: 10-17, 2010.
24. Lesher EL, Berryhill JS. Validation of the Geriatric Depression Scale-Short Form among inpatients. J Clin Psychol 50: 256-260, 1994.
25. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9: 179-186, 1969.
26. Park B, Jun JK, Park J. Cognitive impairment and depression in the early 60s: which is more problematic in terms of instrumental activities of daily living? Geriatr Gerontol Int 14: 62-70, 2014.
27. Toba K, Nakai R, Akishita M, et al. Vitality Index as a useful tool to assess elderly with dementia. Geriatr Gerontol Int 2: 23-29, 2002.
28. Okuyama T, Sugano K, Iida S, Ishida T, Kusumoto S, Akechi T. Screening performance for frailty among older patients with cancer: A cross-sectional observational study of two approaches. J Natl Compr Canc Netw 13: 1525-1531, 2015.
29. Hurria A, Gupta S, Zauberer M, et al. Developing a cancer-specific geriatric assessment: a feasibility study. Cancer 104: 1998-2005, 2005.